`William R. Michalson, Ph.D. on 02/05/2016
`
`Page 1
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`Petitioner
`
`
`
`V.
`
`Adidas AG,
`
`
`
`
`
` Case NO. IPR2015—OO698
`
`
`
` Patent No. 8,092,345
`
`Patent Owner
`
`
` FEBRUARY 5 ,
`2 O 16
`9:45 A.M.
`
`
`
`
`DEPOSITION OF WILLIAM R. MICI-IALSON, Ph.D.
`
`
`20
`
`
`KILPATRICK TOWNSEND 8: STOCKTON LLP
`
`
`
`1.100 PEACI-ITREE STREET, N.E.
`SUITE 2800
`
`ATLANTA, GEORGIA
`
`
` SUZANNE BEASLEY , RPR
`CCR-B- 1184
`
`
` Exhibit 2075
`
`
`Bradium Technologies LLC - patent owner
`
`
`Microsoft Corporation - petitioner
`|PR2016-00448
`
`www.huseby.com
`
`Huseby, Inc. Regional Centers
`
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Hous
`
`1
`
`Under Armour, Inc.,
`
`1
`
`
`
`UNDER ARMOUR, INC. vs. ADIDAS AG
`Page 1
`William R. Michalson, PILD. on 02/05/2016
`
` UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`Under Armour, Inc.,
`
`Petitioner
` V.
`
`Adidas AG, Patent Owner
`
`Case NO.
`
`IPR20l5—OO698
`
`
`
` Patent No. 8,092,345
`
`
`
`
`DEPOSITION OF WILLIAM R. MICHALSON, Ph.D.
`
`
`
`
` FEBRUARY 5, 2016
`9:45 A.M.
`
`KILPATRICK TOWNSEND & STOCKTON LLP
`
`1100 PEACHTREE STREET, N.E.
`SUITE 2800
`
`
`
`
`
`20
`
`
`
`
`ATLANTA, GEORGIA
`
`
`
`SUZANNE BEASLEY, RPR
`CCR-B-1184
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`1
`
`UA-1012.001
`
`1
`
`
`
`UNDER ARMOUR, INC. vs. ADIDAS AG
`William R. Michalson, Ph.D. on 02/05/2016
`Page2
`
`INDEX TO EXAMINATION
`
`Examination
`
`Page No.
`
`By Mr. Ansley .
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`.
`
`. . .
`
`.
`
`.
`
`.
`
`.
`
`.
`
`. . . . . .. 4
`
`INDEX ED EXHIBITS
`
`Exhibit No.
`
`Exhibit 2002
`Declaration of William R.
`Michelson, Ph.D.
`
`APPEARANCES OF
`On behalf
`
`COUNSEL:
`of the Petitioner:
`
`W. SUTTON ANSLEY, Esq.
`Weil, Gotshal & Manges LL?
`l3DD Eye Street, N.W.
`Suite 900
`
`Washington. D.C.
`(202i G32-7018
`
`20005-3314
`
`sutton.ansley@weil.com
`
`Dn behalf
`
`of the Patent Owner and the Witness:
`JONATHAN D. OLINGER, Esq.
`Kilpatxick Townsend & Stockton LLP
`1100 Peachtree Street. N.E.
`Suite 2300
`
`Atlanta, Georgia
`(404) 515-6500
`
`30309
`
`jo1ingerekilpatricktownsend.com
`
`I-IGIDCD-Jfl\l1’I|hUJf0l—'
`
`PI--
`I-'H
`I4Lu’
`P.b-
`
`Ol9@—JO\U|\l|-tn-‘lxll-‘
`
`I—'
`I-' I-'
`|—' M
`|-'us
`|—'uh
`I—' U‘!
`I-—' Bl
`I-‘-J
`I-0 [I3
`I-'\D
`M D
`{U 9-‘
`M M
`M DJ
`to A
`to UI
`
`|~‘EKDUJ-JU'\U'I|5L-Jld1—‘
`
`I-‘|—'
`1-‘B)
`1-‘Lu‘
`I-'sli-
`I-3U'|
`|—'UN
`I-'-J
`I—‘CO
`|-'LO
`[UQ
`I0|-'
`[UI\J
`Ix)(ad
`to#5
`B)U’!
`
`|—'@\.DCD‘-J0\Ll'lIbLnJI\3|—‘
`
`I-'I-'
`I-'{U
`I-‘IA-7
`|—‘H3
`I-‘U'I
`|--‘O\
`I-‘'-J
`|‘-‘to
`|—‘L!)
`l\J C)
`[QI—'
`[QL.)
`{\JDJ
`[0vii
`I'\JU1
`
`Pages 2.5
`Page4
`
`(The signature of the witness to the
`deposition was reserved.)
`WILLIAM R. MICHRLSON, Ph.D.,
`having been duly sworn, was examined and testified
`as follows:
`
`EXAMINRTIO
`
`BY MR. ANSLEY:
`
`Q.
`
`Hello again. Dr. Michalson.
`Hello.
`
`We just concluded the deposition for IPR
`Q.
`proceeding that ends in 697. Now we're moving on to
`the IPR proceeding that ends in 598 for U.S. Patent
`No. 8,092,345.
`
`Again,
`
`same rules as last time. You
`
`understand?
`A.
`
`Yes.
`
`(Exhibit 2002 was marked for
`identification.)
`BY M. ANSLEY:
`
`so I've already handed you Elxhibit 2002.
`Q.
`Are you familiar with this document?
`A.
`Yes.
`
`Let's turn to page 35. And :i.n Section 13
`Q.
`you provide analysis of secondary considerations; is
`that correct?
`
`A.
`
`That ' a correct.
`
`Page5
`
`And let's turn to paragraph 74. And in 74
`Q.
`you mention the MapMyFitness rrcbile applications and
`state, "It is my conclusion that the commercial
`success of these mobile applications supports a
`finding that the instituted claims are not obvious."
`Do you see that?
`A.
`Yes.
`
`And in particular if you go to
`Q.
`paragraph 75, you state that MapMyFitness is evidence
`of commercial success; is that correct?
`A.
`I don't see the particular turn of phrase
`you used.
`Sorry.
`Q.
`I was just asking you to confirm
`that you lay out your evidence for what -- for your
`opinion that the MapMyFitness mobile applications are
`evidence of commercial success.
`Is that correct?
`
`On paragraph '75 I elaborate on that
`A.
`op:i.nion, yes.
`And then in paragraph 7'? you state
`Q.
`Okay.
`that -- sony, I've got the wrong paragraph here.
`Give me one second.
`
`All right, 76. You state in your opinion,
`the coumercial success of the MapMyFitness suite of
`products is plainly demonstrated by the number of
`
`Huseby, Inc. Regional Centers
`www.huseby.c0m
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`800-333-2082
`
`UA—1012.002
`
`2
`
`
`
`UNDER ARMOUR, INC. vs. ADIDAS AG
`William R. Michalson, Ph.D. on 02/05/2016
`Page 6
`MapMyF'itness users and Under Arrnour's purchase of
`MapMyFitness. Do you see that?
`A.
`I do.
`
`Pages 6..9
`Page 8
`
`the profitability of a
`hypothetically,
`company may be due to a number of factors.
`I would have to analyze what that —— I
`would have to look and see what that
`
`profitability was due to. That's not what
`I'm talking about here in paragraph 76.
`BY MR. ANSLEY:
`
`I understand you're not talk_i.ng about that
`Q.
`here. Well, so you mentioned two things. Again,
`it's the nlrriber of WEE‘ users and Unda Armour's
`
`purchase of MM? would be the two factors that you
`considered.
`
`Would there be any other factors that you
`would want inforrretion -- I'm sorry.
`Would there be any other information that
`you would want to see to assess whether or not the
`MapMyFitness suite of products are corrmercially
`successful?
`
`MR. OLINGER: Objection.
`Outside the scope.
`THE WITNESS:
`
`I wasn't asked to
`
`Form.
`
`consider any other factors and I didn't
`You know, if
`consider any other factors.
`there were more factors that were brought
`to my attention or that I obtained, I would
`
`consider them, but I did not do that
`analysis.
`BY MR. ANSLEY:
`
`Do you consider yourself an expert in
`Q.
`evaluating whether a product is a commercial success?
`MR. OLINGER: Objection.
`Form.
`'1‘!-EEWITNESS:
`Ihaveinthepastbeen
`asked to provide opinions about technology
`and likelihood of success of technologies
`offered by different octrpanies, both, you
`know, by entrepreneurial groups and also in
`some of my own endeavors trying to do
`technical evaluations of companies and my
`assessrrent of likelihood of their
`
`So I certainly have some
`longevity.
`atperience in that area.
`BY MR. ANSLEY:
`
`Well, I didn't ask you if you had
`Q.
`experience in the area.
`I asked you if you consider
`yourself an expert in evaluating whether a product is
`a commercial success or not.
`
`Form.
`MR. OLINGER: objection.
`THE WITNESS:
`I think that I have
`
`enough knowledge about the field to be able
`to look at some of the typical indicators
`
`|-‘GLOW-Ja\U1uhuJhJ|—I
`
`I-‘I-‘
`I-‘N
`I-'w
`I-‘>13
`I-'U1
`0-‘U\
`1—''-1
`I-‘(in
`‘I-‘(0
`Is)C)
`(U$-‘
`ts)IQ
`IQUJ
`P0nh
`IDU1
`
`I-‘C)LD$~JO\lJ'|IP-hLIJ}\Jl—|
`
`F‘I-‘
`P‘I0
`1-’LI-P
`I-‘I35
`I-‘U'I
`I-‘Ch
`I-‘i-J
`I-‘CD
`
`So hypothetically would the profitability
`Q.
`of MapMyFitness as a oonpany be a relevant factor in
`your opinion to determining whether its products were
`cormercially successful or not?
`MR. OLINGER:
`Obj ection.
`
`Form.
`
`Outside the scope.
`Tl-IE WITNESS:
`
`can you state that
`
`question again?
`BY MR. ANSLEY:
`
`Q.
`
`Sure.
`
`So you rrention two factors here.
`In paragraph 75 you state that commercial success is
`demonstrated, A, by the number of t-‘MF users, and, B,
`Under Armour's purchase of Map‘-!yFitness.
`And my question is hypothetically would
`the profitability of Map}-iyFitness as a company be a
`relevant factor in your opinion to determining
`whether its products were a cotrmercial success?
`Form.
`MR. DLINGER: Objection.
`Outside the scope.
`In paragraph 76 I'm not
`THE WITNESS:
`referring to the profitability of
`MapMyFitness.
`I'm referring to the nurrher
`
`‘Page '1'
`of users they accumulated and the fact that
`Under Armour purchased the corrpany.
`BY MR. ANSLEY:
`
`I understand that, but I'm asking a
`Q.
`hypothetical. Would the profitability of
`MapMyFitness be a relevant factor in your
`consideration if you have that information available
`to you?
`
`Form.
`
`MR. GLINGER: Objection.
`Outside the scope.
`‘
`THE! WITNESS: Well, hypothetically if
`I had the information available to me, I
`would review that information and determine
`
`if it appeared as if it made —— if it was
`also an indicator of conmercial success.
`
`Without that information I can't really do
`that analysis.
`I would have to do that
`analysis.
`BY MR. ANSLEY:
`
`So without that information, you can't say
`Q.
`one way or another whether or not the company's
`profitability would be a relevant factor?
`Form.
`MR. OLINGER: Objection.
`Outside the scope.
`'I'E-IE: WITNESS: Again speaking
`
`I-‘ELDCD-u.IO\|J'1|C¥LnJlQI-‘
`
`I—'I—'
`I-‘BJ
`I-‘Ln-V
`I-‘oh
`I-‘U1
`I-‘U\
`I-‘-J
`I-‘w
`I-‘U!
`
`I-‘QLOED-_'lO'\lJ‘Irl5buJl\J§-‘
`
`I-‘I-‘
`I-‘Is)
`I-'(ad
`I-‘53-‘-
`I-'U1
`I-‘O'\
`F-‘--.‘l
`I-‘(13
`I-‘\.D
`EdD
`[UI-‘
`[0Ex.)
`[UUJ
`PG13*
`
`www.huseby.com
`Huseby, Inc. Regional Centers
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`800-333-2082
`
`UA-1-012.003
`
`3
`
`
`
`UNDER ARMOUR, INC. vs. ADIDAS AG
`William R. Michalson, Ph.D. on 02105/2016
`Page 10
`of success and determine if that, you know,
`at least represents to me something that is
`commercially successful.
`BY MR. ANSLEY:
`
`Pages 10..13
`Page 12
`
`Form.
`
`MR. OLINGER: Objection.
`Outside the scope.
`I don't recall if I've
`'I'HE WITNESS:
`looked at those details or not.
`BY MR. ANSLEY:
`
`I-‘©LO$-JO\U'|IhLIJI\Jl—‘
`
`I-‘I-‘
`I-‘[U
`I-‘D)
`I-‘>5
`I-‘U1
`I-‘U'\
`I-‘-J
`I-‘@
`I-‘U3
`Ix)Q
`I0I-‘
`ION)
`IOU)
`K)nb
`l\JU'I
`
`I-‘$l.D$-JD'\U'||#-LA3I\J|-I
`
`!-'I1--
`I-‘Ix)
`I-‘DJ
`I-‘nk
`I-‘U1
`I-‘ON
`I-‘—J
`I-‘®
`I-‘ID
`I\.}D
`l\JI-‘
`I\.?B.)
`l\JLIJ
`N}I3-
`
`So you said you think given enough
`Q.
`knowledge about the field.
`Is it your testimony then
`under oath that you think you're an expert in
`evaluating whether a product is a cotrmercial success?
`MR. OLINGER: Objection.
`‘II-IE WITNESS:
`I stand by what I say
`in paragraph '76.
`I'm offering an opinion
`that based on the number of MNEE‘ users and
`
`the purchase of MMF, that it appears that
`those products were at least successful
`enough to get bought up. And presumably
`Under Armour would not have purchased MMF
`ii they didn't think they were going to
`make money with that suite of products.
`BY MR. ANSLEY:
`
`I want to get to that in a second, that
`Q.
`last thing you said, but so you're not saying one way
`or the other whether you're an expert or not in
`evaluating the comrercial success of products?
`MR. OLINGER: Objection.
`Form.
`THE WIINESS:
`I'm not evaluating the
`
`Page 11
`
`oomrercial success in the same sense that
`
`somebody who's in the business of
`evaluating the business aspects of
`companies would evaluate those companies.
`I'm looking at, you know,
`the number of
`users.
`I'm looking at,’you know,
`the
`purchase,
`the feedback that I've cited in
`this report. And in my opinion,
`those
`things are indicators of colrmercial
`success.
`
`BY MR. ANSLEY:
`
`So let's talk about the purchase of
`Q.
`MapMyFitness by Under Armour.
`In the end of
`paragraph 75 you state, "In December 2013
`Under Armour acquired MapMyFituess for $150 million."
`Do you see that?
`A.
`Yes.
`
`Andsothis isoneofthehases,oneof
`Q.
`the two bases for your opinion that the MapMyF‘itness
`suite of products has been a commercial success?
`A.
`Correct.
`
`Do you lcnow how MapMyFitness,
`Q.
`valuation for -- strike that.
`
`the
`
`Do you know how the $150 million valuation
`was calculated?
`
`!-'(3\D®-..IU\U‘lIFklAJl\JI—‘
`
`I-‘I-‘
`I-‘[U
`5-‘Lad
`|--‘#3-
`Ir-‘U1
`I-‘U'\
`I-‘—J
`I-‘3
`Ir-'LD
`Id 3
`Is.)I-‘
`L}Pd
`IHJLIJ
`l\J#-
`[UU’!
`
`I-‘SL133-.‘lU\U'IvhloJl\J|-'
`
`I-‘I-‘
`I-‘IN)
`I-‘UJ
`I-‘lb
`I-‘U1
`I-‘O'\
`I-‘-J
`I-‘3
`I-‘LD
`Rd E
`l\JI-‘
`B)l\J
`l\JLA’
`I\J#-
`IdU'|
`
`So if there's any confidential information
`Q.
`you don't want to disclose, just let me know, but if
`you are aware of confidential information I'd ask you
`not to disclose that here.
`
`But your testirony is you don't recall
`whether you've seen how Under Armour came to the
`conclusion that MapMyFitness was worth $150 million?
`You can answer.
`
`I'm trying to hear flue
`MR. OLINGER:
`question so I can decide whether or not to
`make an objection.
`I'm not preventing him
`answering.
`Form.
`Objection.
`can you ask the
`THE WITNESS:
`question again, please?
`BY MR. ANSLEY:
`
`So you testified that you do not
`Sure.
`Q.
`recall if you looked at the details of how
`Under Armour calculated the $150 million for the
`purchase price of MapMyFitness; is that correct?
`
`A.
`
`That ' s correct .
`
`Page 13
`
`so you don't know here, sitting here,
`Q.
`whetha they paid $149 million for capital
`investments, employees, know-how,
`things like that,
`and $1 million for the product itself, the underlying
`technology of the product itself?
`MR. OLINGER:
`Form.
`Objection.
`‘II-IE WIZINESS:
`offhand I don't recall
`that breakdown.
`BY MR. ANSLEY:
`
`But you don't know one way or the other
`Q.
`how this $150 million was calculated?
`MR. OLDIGER: Objection to form.
`Tl-IE WIINESS: As I said. I don't
`recall if I've seen that breakdown or not,
`but sitting here today, I don't recall how
`that was calculated.
`BY MR. ANSLEY:
`
`And you don't cite any evidence in your
`Q.
`declaration about how that evidence was calculated,
`
`do you?
`
`Form.
`MR. OLINGER: Objection.
`THE WI'INE'.SS:
`I don't believe so.
`BY MR. ANSLEY:
`
`Q.
`
`Do you have any expertise in evaluating
`
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`800-333-2082
`
`UA—1012.004
`
`4
`
`
`
`UNDER ARMOUR, INC. vs. ADIDAS AG
`William R. Michelson, Ph.D. on 02/05/2016
`Page 14
`
`BY MR. ANSLEY:
`
`Pages 14..17
`Page 16
`
`kflm--J0'\I.r|vU=-L»-|hJI—'
`
`I-‘3
`l-‘I-'
`|—'l.\J
`I-'la)
`I—'nh
`I-5U’!
`I-'(h
`|—''-d
`I-‘an
`I-'\.D
`ND
`M1-‘
`L1M
`EuL-J
`Xx}vh-
`idD1
`
`I-'BLDG!-JO'|U'|#IlAJh!|-'
`
`I-‘I-'
`
`|-‘DJ
`I—'uh
`|-'U’!
`|—'K1‘!
`I-‘--I
`I—'(J3
`I-‘‘D
`N! 3
`LI|-‘
`ks)Id
`l\JLo-I
`NJnth
`[UU1
`
`I'm confused on what you said. You said,
`Q.
`"Most of my experience in that area has been on the
`
`purchase of technology from a company." Do you mean
`that you've actually purchased technology from a
`company?
`In what sense do you rrean?
`A.
`I've been in --
`
`MR. OLDJGER: Objection to form.
`THE: WITNESS:
`I've been involved with
`
`startups that may need to acquire
`technology and try to get -— to try to hit
`certain cross-targets. Sozretines that's
`relatively new technology and there may be
`multiple corrpetitors in that technology
`niche. so I've certainly reviewed ccrrpeting
`technologies,
`reviewed the companies that
`are offering competing technologies. and
`tried to provide advice based on those
`evaluations that I've made.
`BY MR. ANSLEY:
`
`So how many startups have you been
`Q.
`involved with in this role?
`
`Form.
`MR. OLINGER: Objectim.
`THE WITNESS: Startups of my own,
`I have also been contacted two or
`
`two.
`
`three titres by others to, you know.
`evaluate a technology.
`BY MR. ANSIEY:
`
`So you have been involved in
`All right.
`Q.
`two of your own startups and you've been contacted
`two or three times about evaluating technologies; is
`that correct?
`A.
`Correct.
`
`let's talk about two of those
`Okay.
`Q.
`startups. Did you ever assign a dollar amount to
`your company on any of those two startups?
`MR. OLINGER: Objection.
`Form.
`Outside the scope.
`THE WITNESS:
`
`on the first of those
`
`startups, we did develop a business plan.
`I participated in the development of that
`b11S2i.I1ESS plan, and part of that involved
`determining what we thought the value of
`thecompanywouldbeat start whenwewere
`trying to pursue venture funding.
`BY MR. ANSLEY:
`
`So you say you participated in the
`Q.
`business plan. Did you actually -- did you actually
`develop, work on developing what the value of the
`company should be?
`
`whether a product -- sorry.
`Do you have any expertise in valuing
`
`ooupanies?
`
`Form.
`MR. OLDJGER: Objection.
`THE WITNESS: Corrpanies, no.
`BY MR. ANSLEY:
`
`And have you ever evaluated a
`Q.
`conpany -- I'm assuming then you've never evaluated a
`company based on the Comnercial success of its
`products;
`is that correct?
`Form.
`MR. OLINGER: objection.
`THE WI'I'N'£S:
`I don't think that's
`
`entirely correct, but I want to be careful.
`BY MR. ANSLEY:
`
`Well, you said you've never had any
`Q.
`eamerience evaluating companies, so I mean logically
`it must follow that you've never had any experience
`valuating companies based on the commercial success
`of the products; isn't that right?
`Form.
`MR. OLLNGER: Objection.
`THE WTINESS: Let me be careful and
`
`clarify what I'm thinking about here. The
`phrase "evaluating companies“ --
`BY MR. ANSLEY:
`
`Q.
`
`Valuating.
`
`Page 15
`the
`Valuating corrpanies has, you know.
`A.
`connotation of determining what the conpany is worth,
`you know,
`in the market, if you will.
`I have
`certainly evaluated companies based on their products
`and success of flzeir products in determining whether
`new product offerings stand a chance of surviving in
`the marketplace.
`‘I‘hat piece I have done.
`Q.
`When you say "evaluating," do you mea.n
`assigning a number to that product?
`MR. OLINGER: Objection. Vague.
`Objection.
`Form.
`BY MR. ANSLEY:
`
`Q.
`
`And by number, I mean a dollar arrount.
`MR. OLDGGELR: Objection.
`Form.
`'I'HE WIINES: Most of my experience
`in that area has been on the purchase of
`technology from a company, so determining
`what the dollar value of a product is now,
`what its likely trajectory and cost would
`be, what its likelihood of success would
`be, is something that I've certainly dealt
`with. And sornetirres that involves seeing
`how the corrpany has worked with other
`products.
`
`LDCD-u.IO\U1:li|.nJi\J|—‘
`
`P4Q
`I-‘I-‘
`|—'M
`I-'1;)
`I—'uh-
`U.
`I-'Ch
`I-'-J
`I—'an
`|—'ID
`l\JG
`t\J1-'
`NIto
`NU-1
`N:5
`M01
`
`|-‘GLDOD-uJO\LJ'|thLAJI\J|—'
`
`I-‘I-‘
`
`S I
`
`-‘‘I1
`|—'I]:-
`I-‘U’!
`|—'tn
`I-‘-o.I
`FCh
`|-'lo
`Ix)S
`id1-‘
`[JIx)
`l\JLA’
`l\JDB
`30U1
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.l1useby.com
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`5
`
`UA-1012.005
`
`5
`
`
`
`I-‘Cjlolxl-Jfl\LJ'Inb-bJhJl-3
`
`I-‘I-‘
`9-‘[Q
`i-‘LJ
`9-‘oh
`l--‘U’!
`l-|U\
`I----J
`I-'I3
`I—'KD
`M3
`L) |—'
`h)['9
`[0L0
`idsh-
`LIU’!
`
`|-‘GKDUIIW-lU\U'|nh.laJf\3I-‘
`
`|—'|—'
`I-‘N
`I—'(ad
`I-‘uh
`I—'LFI
`I-‘U'\
`I—''-I
`
`Form.
`
`MR. OLILGER: Objection.
`Outside the scope.
`THE WITNESS: Not solely, but I was
`involved in that process.
`BY MR. ANSLEY:
`
`How were you involved?
`Q.
`We're rolling back the clock quite a ways
`A.
`here. Myself and another of the principals of that
`company had several meetings with -- there was a
`small business development council in Worcester,
`Massachusetts that we also worked with, and we would
`accumulate information about the market. we would
`
`accumulate information about what we thought our
`costs were going to be, what we thought our sales
`numbers were going to be, and, you know, we worked
`with that small business advisor, you know, to
`develop a marketing plan and a, you know, basically a
`business development plan that would allow us to go
`out and seek funding, a.nd that included coming up
`with an idea of the value of our corrpany in the
`marketplace.
`I don't recall all the specific details of
`what we did.
`I'd have to go back through my notes
`and look at that business plan again, but I know that
`myself and one other person wrote the majority of
`
`that plan.
`Q.
`
`Why did you use a small business advisor?
`Form.
`MR. OLINGER: Objection.
`THE WITNESS: Because it was a new
`
`Page 19
`
`group that had formed at Clark University.
`They were a free service. They were
`
`at what we were
`another set of eyes to
`thinking.
`'Ihey were able to identify
`certain things that we missed.
`They also had an arty of graduate
`students that were able to assist us in
`
`doing some of our research as we were
`Soitwasa
`putting together that plan.
`helpful resource and it was locally
`And I
`available and it was low cost.
`
`forget who referred us to them, but it was
`basically on a reference.
`BY MR. ANSLEY:
`
`So I understand that you were
`Q.
`involved -- you say that you've been involved in
`valuing you.r own company, your own two startups, and
`you've been contacted two or three times about
`startups?
`A.
`Q.
`
`Well, I had a colleague who was —-
`Yes, just keep it short. That's fine.
`
`UNDER ARMOUR, INC. vs. ADIDAS AG
`William R. Michelson, Ph.D. on 02/05/2016
`Page 18
`
`Pages 18..21
`Page 20
`Can you ask the question again, please.
`A.
`Sure.
`You said
`Q.
`I just want to surrmarize.
`that you had two startups of your own and that you've
`been contacted two or three times by -- was it by
`startups?
`It was by somebody that was involved with
`A.
`venture capital that was evaluating proposals that
`were in front of them.
`
`Simple question. Did you ever run
`Okay.
`Q.
`the calculations -- I understand you said you were
`involved. Did you ever actually run the calculations
`of what the value of any of these companies are?
`Form.
`MR. OLZENGER: Objection.
`BY MR. ANSLEY:
`
`It's a simple yes or no.
`Q.
`It's a sirrple yes or no for you, but I'm
`A.
`rolling back 20 years and thinking about the one that
`I was most closely involved with calculations there.
`I'm sure that I worked with those
`
`spreadsheets and adjusted numbers in those
`spreadsheets. which would result in different
`valuations for the corrpany, so when you say did I
`actually run those numbers, I think the answer
`
`probably is yes, but I'd have to go back, and we're
`talking 20 years ago.
`
`Page 21
`Sure. But you're talking about editing
`Q.
`certain fields on a spreadsheet; is that right?
`A.
`But also understanding how those fields
`impacted other fields and --
`Q.
`I understood that.
`A.
`-- seeing what those calculations were and
`developing some understanding of what that process
`was.
`
`So if the question is have I ever run
`those calculations, I think the answer is probably
`yes.
`
`Okay. of the $150 million that
`Q.
`Under Armour paid for Mapmyl-‘itness, how much do you
`think of that $150 million was attributable to the
`Map\1yFitness products?
`Form.
`MR. OLINGER: Objection.
`Tl-IE WITNESS:
`sitting here today, I
`don't know.
`BY MR. ANSLEY:
`
`Let's assume hypothetically that
`Q.
`MapMyFitness exceeded Under Armour's expectation in
`terms of performance since the acquisition, okay?
`It's just a hypothetical. Would that be a relevant
`consideration for you in judging whether the
`MapMyFitness application is and has been a commercial
`
`P’D\.DCD-—..IU'\U'l|hv|AJtx)I-‘
`
`P‘5-'
`I-‘I0
`F-‘LI-V
`|—‘IF-
`I—‘U'l
`|—‘U'\
`|—''-J
`l--’E)
`|--‘\D
`(«J Q
`[Ul-‘
`PdI\J
`IKJbl
`l\JFF.
`l\JU1
`
`I-'DLOE-.‘lO'\lJ1vB-|.II!l‘sJ1—'
`
`|—'|—'
`|-‘hi
`I—'LAJ
`I—'#-
`|—'U'|
`|—'ON
`I—'-J
`1-‘CU
`|—'LD
`R)Q
`Ix)I-'
`[U10
`IdLA)
`blIh
`Ex)U'I
`
`www.huseby.com
`Huse-by, Inc. Regional Centers
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`800-333-2082
`
`UA-1012.006
`
`6
`
`
`
`I-'DLDU)-.I0'\UI-lav-lI\J|—'
`
`|-‘|—'
`|---‘l\.)
`P’LAJ
`I-‘yt-
`|—'U'|
`I-'O'\
`l—'--J
`HG:
`I-'\D
`20$
`[U|-'
`NPIx)
`IdLAJ
`tush
`toU'|
`
`success if it outperformed its eameotations?
`FOIN.
`MR. OLINER: Objection.
`Outside the scope.
`THE! WIINESS: Well, hypothetically it
`may be a consideration, but I'd have to
`study that to determine how rroch it
`mattered, if it mattered.
`BY MR. ANBLEY:
`
`And then the opposite, is it your opinion
`Q.
`that if MapMyPitness was underperforrning, it might be
`a consideration. but you'd have to again study that
`data?
`
`Form.
`
`MR. OLINGER: Objection.
`Outside the scope.
`'I'HE WITNESS: Well, again,
`hypothetically there are a lot of factors
`that may be involved, so you'd have to
`study the situation.
`I've not been asked
`to do that analysis so I haven't done that
`analysis.
`BY MR. ANSLEY:
`
`So you were just asked to look at the
`Q.
`$150 million purchase price and the umber of users,
`and based on those two data points, you concluded
`that the MapMyFitness suite of products is a
`
`comnercial success: is that right?
`Form.
`MR. GLINGER: Objection.
`THE WITNESS: That's one of the
`
`firings that I did when we're talking about
`paragraphs 75 and 76 right now.
`I mean,
`there's other material in my report.
`BY MR. ANSLEY:
`
`But you didn't ask to see any other data
`Q.
`in evaluating whether MapMyFitness is a commercial
`success?
`
`MR. OLINGEIR: Objection.
`Outside the scope.
`IKE WIINESS: Relative to those
`
`Form .
`
`paragraphs that we're discussing, no.
`MR. ANSLEY: No more questions.
`MR. OLJNSER: Let's take a brief
`
`fiVe—minute break, please.
`(A recess was taken.)
`MR. OLINGEER: No questions for this
`witness.
`We consider the deposition
`closed.
`
`(Deposition ooncluded at 10:25 a.m.)
`
`F‘IDIDCD-.JU\l.}'||FhlI'd|-’
`
`I-' I-'
`I-‘N
`I-'Ll
`I-'uh
`|-'U'|
`I-'O}
`H -J
`I—‘ [ill
`
`|-‘ ID
`
`UNDER ARMOUR, INC. vs. ADIDAS AG
`William R. Michalson, Ph.D. on 02/05/2016
`Page22
`
`Pages 21.25
`Page 24
`S H E E T
`E R R A T A
`Pursuant to Rule 3D(e) of the Federal Rules of
`Civil Procedure and/or the Official Code of Georgia
`Annotated 9-11-3D(e} any changes in form or substance
`which you desire to make to your deposition testimony
`shall he entered upon the deposition with a statement
`of the reasons given for making them.
`
`To assist you in making any such corrections.
`please use the form below. If supplemental or
`additional pages are necessary, please furnish same
`and attach them to this errata sheet.
`
`the undersigned. WILLIAM R. MICHALBON. Ph.D..
`I.
`do hereby certify that I have read the foregoing
`deposition and that to the best of my knowledge said
`deposition is true and accurate (with the exception
`of the following corrections listed below).
`
`Line
`Page
`Reason for change:
`
`should read:
`
`Line
`Page
`Reason for change:
`
`should read:
`
`Line
`Page
`Reason for change:
`
`should read:
`
`Line
`Page
`Reason for change:
`
`should read:
`
`Line
`Page
`Reason for change:
`
`should read:
`
`Line
`Page
`Reason for change:
`
`should read:
`
`Line
`Page
`Reason for change:
`
`should read:
`.
`
`Line
`Page
`Reason for change:
`
`should read:
`
`Line
`Page
`Reason for change:
`
`Line
`Page
`Reason for change:
`
`should read:
`
`should read:
`
`Signature
`
`Sworn to and Subscribed before me
`
`day of
`This
`My Commission Expires:
`
`. Notary Public.
`,
`
`800-333-2082
`www.huseby.c0m
`I-Iusehy, Inc. Regional Centers
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco ‘
`
`7
`
`UA-1012.007
`
`7
`
`
`
`UNDER ARMOUR, INC. vs. ADIDAS AG
`William R. Michalson, Ph.D. on 02/05/2016
`
`Pages 26..27
`
`F‘OIOHJW-lU\Ll'1IhhJhJ?"'
`
`F‘I"
`|"N
`1''LI-I
`3'"ilk
`P"U’!
`I-' 0'!
`|-‘ -J
`|-' U!
`I-' ll)
`[U D
`|\3 I-'
`toN
`M DU‘
`[0vb
`N U‘
`
`m--lmlnnbl.-JNII-|
`
`C E R T I F I C A T E
`
`GEORGIA:
`FULTON COUNTY:
`
`I hereby certify that the
`foregoing deposition was reported, as
`stated in the caption, and the questions
`and answers thereto were reduced to the
`
`written page under my direction; that the
`foregoing pages 1 through 23 represent a
`true and correct transcript of the evidence
`
`I further certify that I am not in
`given.
`any way financially interested in the
`result of said case.
`
`Pursuant to Rules and Regulations
`of the Board of Court Reporting of the
`Judicial Council of Georgia, I make the
`following disclosure:
`I am a Georgia Certified Court
`I am here as an independent
`Reporter.
`contractor for Huseby.
`Inc.
`
`Page27
`
`I was contacted by the offices
`Inc.
`to provide court reporting
`of Huseby,
`services for this deposition.
`I will not
`be taking this deposition under any
`contract that is prohibited by O.C.G.A.
`15-14-37 (al or (b).
`I have no written contract to
`
`provide reporting services with any party
`to the case, any counsel in the case, or_
`any reporter or reporting agency from whom
`a referral might have been made to cover
`this deposition.
`I will charge my usual
`and customary rates to all parties in the
`case.
`
`This,
`
`the 10th day of February. 2016.
`
`SUZANNE BEASLEY, B-1154
`My commission expires on the
`24th day of August, 2013.
`
`800-333-2082
`Huseby, Inc. Regional Centers
`www.huseby.com
`Charlotte ~ Atlanta ~ Washington, DC ~ New York ~ Houston ~ San Francisco
`
`UA-1012.008
`
`8
`
`